Delaware
|
000-51481
|
13-3986004
|
(State or Other
|
(Commission File
|
(I.R.S. Employer
|
Jurisdiction of
|
Number)
|
Identification No.)
|
Incorporation)
|
|
|
|
100 Lakeside Drive, Suite 100, Horsham, Pennsylvania
|
19044
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
10.1 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Accelmed
|
10.2 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Broadfin
|
10.3 |
Securities Purchase Agreement dated as of March 30, 2018 between the Company and Sabby
|
10.4 |
Form of Registration Rights Agreement
|
10.5 |
Form of Leak-Out Agreement
|
10.6 |
Form of Voting Undertaking
|
10.7 |
Form of Subscription Agreement
|
10.8 |
Employment Agreement dated March 30, 2018 between the Company and Dr. Dolev Rafaeli
|
|
STRATA SKIN SCIENCES, INC.
|
|
By:
|
/s/ Frank J. McCaney
|
|
|
Frank J. McCaney
|
|
|
President and Chief Executive Officer
|
|
Page
|
|||||
1.
|
PURCHASE AND SALE OF SECURITIES.
|
||||
1.1.
|
Purchased Shares
|
1 | |||
1.2.
|
Closing
|
2 | |||
1.3.
|
Payment of Purchase Price; Delivery of Security
|
2 | |||
2.
|
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
|
2 | |||
2.1.
|
Organization and Qualification
|
2 | |||
2.2.
|
Authorization; Enforcement; Validity
|
3 | |||
2.3.
|
Issuance of Purchased Shares
|
4 | |||
2.4.
|
No Conflicts
|
4 | |||
2.5.
|
Consents
|
4 | |||
2.6.
|
Acknowledgment Regarding Buyer's Purchase of Purchased Shares
|
4 | |||
2.7.
|
No General Solicitation; Placement Agent's Fees
|
5 | |||
2.8.
|
No Integrated Offering
|
5 | |||
2.9.
|
Application of Takeover Protections; Rights Agreement
|
5 | |||
2.10.
|
SEC Documents; Financial Statements
|
6 | |||
2.11.
|
Absence of Certain Changes
|
6 | |||
2.12.
|
No Undisclosed Events, Liabilities, Developments or Circumstances
|
7 | |||
2.13.
|
Conduct of Business; Regulatory Permits
|
7 | |||
2.14.
|
Foreign Corrupt Practices
|
8 | |||
2.15.
|
Sarbanes-Oxley Act
|
8 | |||
2.16.
|
Transactions with Affiliates
|
8 | |||
2.17.
|
Equity Capitalization
|
8 | |||
2.18.
|
Indebtedness and Other Contracts
|
9 | |||
2.19.
|
Absence of Litigation
|
||||
2.20.
|
Insurance
|
10 | |||
2.21.
|
Employee Relations
|
10 | |||
2.22.
|
Pensions
|
11 | |||
2.23.
|
Personal Property
|
11 | |||
2.24.
|
Real Property.
|
11 | |||
2.25.
|
Intellectual Property Rights
|
12 | |||
2.26.
|
FDA
|
13
|
|||
2.27.
|
Healthcare Matters
|
15 | |||
2.28.
|
Environmental Laws
|
16 | |||
2.29.
|
Product Liability and Warranty
|
17 | |||
2.30.
|
Data Privacy
|
17 | |||
2.31.
|
Tax Status
|
17 | |||
2.32.
|
Internal Accounting and Disclosure Controls
|
18 | |||
2.33.
|
Off Balance Sheet Arrangements
|
19 | |||
2.34.
|
Investment Company Status
|
19 | |||
2.35.
|
Acknowledgement
|
19 | |||
2.36.
|
Manipulation of Price
|
19 | |||
2.37.
|
U.S. Real Property Holding Corporation
|
19 |
2.38.
|
Registration Eligibility
|
19
|
||
2.39.
|
Transfer Taxes
|
20
|
||
2.40.
|
Shell Company Status
|
20
|
||
2.41.
|
Illegal or Unauthorized Payments; Political Contributions
|
20
|
||
2.42.
|
Money Laundering
|
20
|
||
2.43.
|
Registration Rights
|
20
|
||
2.44.
|
Accounts Receivable
|
20
|
||
2.45.
|
Relationships with Customers and Suppliers
|
20
|
||
2.46.
|
Incentive Plan
|
21
|
||
2.47.
|
Acknowledgement
|
21
|
3.
|
BUYER'S REPRESENTATIONS AND WARRANTIES.
|
21
|
||
3.1.
|
Organization; Authority
|
21
|
||
3.2.
|
No Public Sale of Distribution
|
21
|
||
3.3.
|
Accredited Investor Status
|
22
|
||
3.4.
|
Reliance on Exemptions
|
22
|
||
3.5.
|
Information
|
22
|
||
3.6.
|
No Governmental Review
|
22
|
||
3.7.
|
Transfer or Resale
|
22
|
||
3.8.
|
Validity; Enforcement
|
23
|
||
3.9.
|
No Conflicts
|
23
|
||
3.10.
|
Availability of Funds
|
23
|
||
3.11.
|
Manipulation of Price
|
23
|
||
3.12.
|
Illegal or Unauthorized Payments; Political Contributions
|
23
|
||
3.13.
|
Money Laundering
|
24
|
||
3.14.
|
Legends
|
24
|
||
3.15.
|
Ownership of Common Stock
|
24
|
||
3.16.
|
Foreign Investors
|
24
|
4.
|
COVENANTS.
|
24
|
||
4.1.
|
Commercially Reasonable Efforts
|
24
|
||
4.2.
|
Corporate Examinations and Investigations
|
24
|
||
4.3.
|
Proxy Statement; Other Required Company Filing; Company Stockholders Meeting.
|
25
|
||
4.4.
|
Form D and Blue Sky
|
27
|
||
4.5.
|
Reporting Status
|
27
|
||
4.6.
|
Use of Proceeds
|
27
|
||
4.7.
|
Financial Information
|
27
|
||
4.8.
|
Listing
|
28
|
||
4.9.
|
Disclosure of Transactions and Other Material Information
|
28
|
||
4.10.
|
Conduct of Business
|
28
|
||
4.11.
|
Buyer Protective Provisions
|
29
|
||
4.12.
|
Additional Offering
|
30
|
||
4.13.
|
No Solicitation
|
30
|
||
4.14.
|
Board Composition; Chairman of the Board; Options
|
32
|
||
4.15.
|
Bylaws and Certificate of Incorporation
|
32
|
||
4.16.
|
D&O Insurance
|
32
|
4.17.
|
Rafaeli
|
33
|
||
4.18.
|
Auditors
|
34
|
||
5.
|
REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.
|
34
|
||
5.1.
|
Legends
|
34
|
||
5.2.
|
Removal of Legends
|
34
|
||
6.
|
CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL.
|
35
|
||
7.
|
CONDITIONS TO BUYER'S OBLIGATION TO PURCHASE.
|
35
|
||
8.
|
TERMINATION.
|
38
|
||
8.1.
|
Termination
|
38
|
||
8.2.
|
Consequences of Termination.
|
39
|
||
9.
|
MISCELLANEOUS.
|
39
|
||
9.1.
|
Governing Law; Jurisdiction; Jury Trial
|
39
|
||
9.2.
|
Counterparts
|
40
|
||
9.3.
|
Headings; Gender
|
40
|
||
9.4.
|
Severability
|
40
|
||
9.5.
|
Entire Agreement; Amendments
|
40
|
||
9.6.
|
Notices
|
41
|
||
9.7.
|
Successors and Assigns
|
42
|
||
9.8.
|
No Third Party Beneficiaries
|
42
|
||
9.9.
|
Survival
|
42
|
||
9.10.
|
Further Assurances
|
42
|
||
9.11.
|
Indemnification
|
43
|
||
9.12.
|
Fees and Expenses
|
44
|
||
9.13.
|
Construction
|
45
|
||
9.14.
|
Remedies
|
45
|
||
9.15.
|
Exercise of Right
|
45
|
Defined Term
|
Section
|
1933 Act
|
Recitals
|
1934 Act
|
Section 2.6
|
8-K Filing
|
Section 4.9
|
Additional Investors
|
Section 7.1.3
|
Agreement
|
Preamble
|
Acquisition Proposal
|
Section 4.13.7
|
Board
|
Recitals
|
Board Recommendation
|
Section 4.3.5
|
Breakup Fee
|
Section 8.2.3
|
Business Day
|
Section 1.2
|
Buyer
|
Preamble
|
Buyer Affiliates
|
Section 4.15.1
|
Buyer's Fees and Expenses
|
Section 9.12
|
Bylaws
|
Section 2.17
|
Certificate of Incorporation
|
Section 2.17
|
Chairman
|
Section 4.14
|
Change of Recommendation
|
Section 4.13.4
|
Closing
|
Section 1.2
|
Closing Date
|
Section 1.2
|
Code
|
Section 2.31
|
Common Stock
|
Recitals
|
Company
|
Preamble
|
Company Disclosure Schedule
|
Section 2
|
Company Intellectual Property
|
Section 2.25.1
|
Company Product
|
Section 2.26.1
|
Company Real Property
|
Section 2.24
|
Company Stockholder Approval
|
Section 2.2
|
Company Stockholders Meeting
|
Section 4.3.1
|
Competent Authority
|
Section 2.26.1
|
Due Diligence Investigation
|
Section 4.2
|
Eligible Market
|
Section 4.8
|
Environmental Laws
|
Section 2.28
|
EU Regulatory Entity
|
Section 2.26.1
|
FDA
|
Section 2.26.1
|
Hazardous Materials
|
Section 2.28
|
Healthcare Laws
|
Section 2.27
|
Indebtedness
|
Section 2.11
|
Insolvent
|
Section 2.11
|
Knowledge
|
Section 2.25.4
|
Last Closing Date
|
Section 8.1.1
|
Losses
|
Section 9.11
|
Major Stockholders
|
Section 7.1.2
|
Material Adverse Effect
|
Section 2.1
|
Medical Regulation
|
Section 2.26.1
|
NASDAQ Letters
|
Section 2.13
|
Non-Affiliates Stock
|
Section 4.15.1
|
Other Required Company Filing
|
Section 4.3.2
|
Person
|
Section 2.1
|
Personal Information
|
Section 2.30
|
Plan
|
Section 2.46
|
Press Release
|
Section 4.9
|
Principal Accelmed Director
|
Section 4.14.1
|
Principal Market
|
Recitals
|
Proxy Statement
|
Section 4.3.2
|
Purchase Price
|
Section 1.1
|
Purchased Shares
|
Section 1.1
|
Rafaeli
|
Section 7.1.3
|
Registrable Securities
|
Section 2.5
|
Registration Rights Agreement
|
Section 7.1.5
|
Registration Statement
|
Section 2.2
|
Regulation D
|
Recitals
|
Related Person Transaction
|
Section 4.15.1
|
Reporting Period
|
Section 4.5
|
Rule 144
|
Section 3.7
|
SEC
|
Recitals
|
SEC Clearance Date
|
Section 4.3.5
|
SEC Documents
|
Section 2.10
|
Stockholders Undertakings
|
Section 7.1.2
|
Subsidiaries
|
Section 2.1
|
Superior Proposal
|
Section 4.13.7
|
Tax
|
Section 2.31.1
|
Tax Returns
|
Section 2.31.1
|
Termination Fee
|
Section 8.2.2
|
Transaction Documents
|
Section 2.2
|
Page | |||
1.
|
PURCHASE AND SALE OF SECURITIES.
|
1 | |
1.1.
|
Purchased Shares
|
1 | |
1.2.
|
Closing
|
2 | |
1.3.
|
Payment of Purchase Price; Delivery of Security
|
2 | |
2.
|
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
|
2 | |
2.1.
|
Organization and Qualification
|
2 | |
2.2.
|
Authorization; Enforcement; Validity
|
3 | |
2.3.
|
Issuance of Purchased Shares
|
4 | |
2.4.
|
No Conflicts
|
4 | |
2.5.
|
Consents
|
4 | |
2.6.
|
Acknowledgment Regarding Buyer's Purchase of Purchased Shares
|
5 | |
2.7.
|
No General Solicitation; Placement Agent's Fees
|
5 | |
2.8.
|
No Integrated Offering
|
5 | |
2.9.
|
Application of Takeover Protections; Rights Agreement
|
5 | |
2.10.
|
SEC Documents; Financial Statements
|
5 | |
2.11.
|
Absence of Certain Changes
|
6 | |
2.12.
|
No Undisclosed Events, Liabilities, Developments or Circumstances
|
7 | |
2.13.
|
Conduct of Business; Regulatory Permits
|
7 | |
2.14.
|
Foreign Corrupt Practices
|
8 | |
2.15.
|
Sarbanes-Oxley Act
|
8 | |
2.16.
|
Transactions With Affiliates
|
8 | |
2.17.
|
Equity Capitalization
|
8 | |
2.18.
|
Indebtedness and Other Contracts
|
9 | |
2.19.
|
Absence of Litigation
|
9 | |
2.20.
|
Insurance
|
10 | |
2.21.
|
Employee Relations
|
10 | |
2.22.
|
Pensions
|
11 | |
2.23.
|
Personal Property
|
11 | |
2.24.
|
Real Property.
|
11 | |
2.25.
|
Intellectual Property Rights
|
12 | |
2.26.
|
FDA
|
13 | |
2.27.
|
Healthcare Matters
|
15 | |
2.28.
|
Environmental Laws
|
16 | |
2.29.
|
Product Liability and Warranty
|
16 | |
2.30.
|
Data Privacy
|
17 | |
2.31.
|
Tax Status
|
17 | |
2.32.
|
Internal Accounting and Disclosure Controls
|
18 | |
2.33.
|
Off Balance Sheet Arrangements
|
19 | |
2.34.
|
Investment Company Status
|
19 | |
2.35.
|
Acknowledgement
|
19 | |
2.36.
|
Manipulation of Price
|
19 | |
2.37.
|
U.S. Real Property Holding Corporation
|
19 |
Page | |||
2.38.
|
Registration Eligibility
|
19 | |
2.39.
|
Transfer Taxes
|
19 | |
2.40.
|
Shell Company Status
|
19 | |
2.41.
|
Illegal or Unauthorized Payments; Political Contributions
|
19 | |
2.42.
|
Money Laundering
|
20 | |
2.43.
|
Registration Rights
|
20 | |
2.44.
|
Accounts Receivable
|
20 | |
2.45.
|
Relationships with Customers and Suppliers
|
20 | |
2.46.
|
Incentive Plan
|
20 | |
2.47.
|
Acknowledgement
|
21 | |
2.48 | Acknowledgment Regarding Buyer's Purchase of Purchased Shares | 21 | |
2.49 | Acknowledgment Regarding Buyer's Trading Activity | 21 | |
3.
|
BUYER'S REPRESENTATIONS AND WARRANTIES.
|
22 | |
3.1.
|
Organization; Authority
|
22 | |
3.2.
|
No Public Sale of Distribution
|
22 | |
3.3.
|
Accredited Investor Status
|
22 | |
3.4.
|
Reliance on Exemptions
|
22 | |
3.5.
|
Information
|
22 | |
3.6.
|
No Governmental Review
|
23 | |
3.7.
|
Transfer or Resale
|
23 | |
3.8.
|
Validity; Enforcement
|
23 | |
3.9.
|
No Conflicts
|
23 | |
3.10.
|
Availability of Funds
|
23 | |
3.11.
|
Illegal or Unauthorized Payments; Political Contributions
|
23 | |
3.12.
|
Money Laundering
|
24 | |
3.13.
|
Legends
|
24 | |
3.14.
|
Ownership of Common Stock
|
24 | |
3.15.
|
Foreign Investors
|
24 | |
4.
|
COVENANTS.
|
24 | |
4.1.
|
Commercially Reasonable Efforts
|
24 | |
4.2.
|
Form D and Blue Sky
|
24 | |
4.3.
|
Reporting Status
|
25 | |
4.4.
|
Use of Proceeds
|
25 | |
4.5.
|
Financial Information
|
25 | |
4.6.
|
Listing
|
26 | |
4.7.
|
Disclosure of Transactions and Other Material Information
|
26 | |
4.8.
|
Additional Offering
|
26 | |
4.9. | Observer Rights | 27 | |
4.10.
|
Non-Public Information | 27 | |
4.11 |
D&O Insurance
|
27 | |
4.12
|
Auditors
|
28 | |
5.
|
REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.
|
28 | |
5.1.
|
Legends
|
28 | |
5.2.
|
Removal of Legends
|
28 | |
5.3 | Failure to Remove Legends | 29 |
Page | |||
6.
|
CONDITIONS TO THE COMPANY'S OBLIGATION TO SELL.
|
29 | |
7.
|
CONDITIONS TO BUYER'S OBLIGATION TO PURCHASE.
|
30 | |
8.
|
TERMINATION.
|
32 | |
8.1.
|
Termination
|
32 | |
8.2.
|
Consequences of Termination.
|
32 | |
9.
|
MISCELLANEOUS.
|
32 | |
9.1.
|
Governing Law; Jurisdiction; Jury Trial
|
32 | |
9.2.
|
Counterparts
|
33 | |
9.3.
|
Headings; Gender
|
33 | |
9.4.
|
Severability
|
33 | |
9.5.
|
Entire Agreement; Amendments
|
33 | |
9.6.
|
Notices
|
34 | |
9.7.
|
Successors and Assigns
|
35 | |
9.8.
|
No Third Party Beneficiaries
|
35 | |
9.9.
|
Survival
|
35 | |
9.10.
|
Further Assurances
|
36 | |
9.11.
|
Indemnification
|
36 | |
9.12.
|
Fees and Expenses
|
37 | |
9.13.
|
Construction
|
38 | |
9.14.
|
Remedies
|
38 | |
9.15.
|
Exercise of Right
|
38 |
Defined Term
|
Section
|
1933 Act
|
Recitals
|
1934 Act
|
Section 2.6
|
8-K Filing
|
Section 4.8
|
Agreement
|
Preamble
|
Board
|
Recitals
|
Business Day
|
Section 1.2
|
Buyer
|
Preamble
|
Buyer's Fees and Expenses
|
Section 9.12
|
Bylaws
|
Section 2.17
|
Certificate of Incorporation
|
Section 2.17
|
Closing
|
Section 1.2
|
Closing Date
|
Section 1.2
|
Code
|
Section 2.31
|
Common Stock
|
Recitals
|
Company
|
Preamble
|
Company Disclosure Schedule
|
Section 2
|
Company Intellectual Property
|
Section 2.25.1
|
Company Product
|
Section 2.26.1
|
Company Real Property
|
Section 2.24
|
Company Stockholder Approval
|
Section 2.2
|
Competent Authority
|
Section 2.26.1
|
Eligible Market
|
Section 4.7
|
Environmental Laws
|
Section 2.28
|
EU Regulatory Entity
|
Section 2.26.1
|
FDA
|
Section 2.26.1
|
Hazardous Materials
|
Section 2.28
|
Healthcare Laws
|
Section 2.27
|
Indebtedness
|
Section 2.11
|
Insolvent
|
Section 2.11
|
Knowledge
|
Section 2.25.4
|
Last Closing Date
|
Section 8.1.1
|
Losses
|
Section 9.11
|
Material Adverse Effect
|
Section 2.1
|
Medical Regulation
|
Section 2.26.1
|
NASDAQ Letters
|
Section 2.13
|
Person
|
Section 2.1
|
Personal Information
|
Section 2.30
|
Plan
|
Section 2.46
|
Press Release
|
Section 4.8
|
Principal Market
|
Recitals
|
Purchase Price
|
Section 1.1
|
Purchased Shares
|
Section 1.1
|
Registrable Securities
|
Section 2.5
|
Registration Rights Agreement
|
Section 7.1.3
|
Registration Statement
|
Section 2.2
|
Regulation D
|
Recitals
|
Reporting Period
|
Section 4.3
|
Rule 144
|
Section 3.7
|
SEC
|
Recitals
|
SEC Documents
|
Section 2.10
|
Subsidiaries
|
Section 2.1
|
Tax
|
Section 2.31.1
|
Tax Returns
|
Section 2.31.1
|
Transaction Documents
|
Section 2.2
|
COMPANY:
|
|||
STRATA SKIN SCIENCES, INC
|
|||
By:
|
|||
Name:
|
|||
Title:
|
BUYER:
|
|||
ACCELMED GROWTH PARTNERS, L.P
|
|||
By:
|
Accelmed Growth Partners Management Ltd.,
its Manager |
||
By:
|
|||
Name:
|
|||
Title:
|
SABBY:
|
|||
Sabby Healthcare Master Fund
|
|||
By:
|
|||
Name:
|
|||
Title:
|
BROADFIN:
|
|||
Broadfin Healthcare Master Fund, Ltd. Ltd.
|
|||
By:
|
|||
Name:
|
|||
Title:
|
ADDITIONAL INVESTORS:
|
|||
Gohan Investments Ltd.
|
|||
By:
|
|||
Name:
|
|||
Title:
|
Dolev Rafaeli
|
TO: |
STRATA Skin Sciences, Inc.
|
1.
|
Subscription for Shares
|
2.
|
Closing.
|
3.
|
Representations, Warranties, Acknowledgments and Agreements of the Subscriber
|
£
|
Subscriber is an individual whose individual net worth, or joint net worth with Subscriber's spouse, exceeds $1,000,000.
|
£
|
Subscriber is an individual who had an individual income (exclusive of any income attributable to Subscriber's spouse) in excess of $200,000 during each of the two most recent years, and reasonably expects to have an annual individual income for the current year in excess of $200,000.
|
£
|
Subscriber is an individual who had joint income with his or her spouse in excess of $300,000 during each of the two most recent years, and reasonably expects to have an annual joint income with his or her spouse for the current year to be in excess of $300,000.
|
£
|
Subscriber is an individual who is a director or an executive officer of the Corporation.
|
£
|
Subscriber is an entity in which all of the equity owners are "accredited investors" (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act).
|
£
|
Subscriber is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"), corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Shares, with total assets in excess of $5,000,000.
|
£
|
Subscriber is a "private business development company" (as such term is defined in Section 202(a)(22) of the Investment Advisors Act of 1940, as amended).
|
£
|
Subscriber is a "bank" (as such term is defined in Section 3(a)(2) of the Securities Act), or a "savings and loan association or other institution" (as such term is defined in Section 3(a)(5)(A) of the Securities Act) whether acting in its individual or fiduciary capacity.
|
£
|
Subscriber is a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended.
|
£
|
Subscriber is an "insurance company" (as such term is defined in Section 2(13) of the Securities Act).
|
£
|
Subscriber is an investment company registered under the Investment Company Act of 1940, as amended, or is a "business development company" (as such term is defined in Section 2(a)(48) of that act).
|
£
|
Subscriber is a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958, as amended.
|
£
|
Subscriber is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974, as amended, and the investment decision is made by a "plan fiduciary" (as such term is defined in Section 3(21) of such act), which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if a self-directed plan, with investment decisions made solely by persons that are "accredited investors" (as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act).
|
4.
|
Miscellaneous
|
COMPANY
|
||
By:
|
||
Signer
|
By:
|
||
Name:
|
||
Title:
|
Average Revenue per Machine ("ARM") during the Quarter
|
Bonus (as percentage of total company revenue for the relevant Quarter)
|
|||||
Up to $8,100
|
0.50
|
%
|
||||
$
|
8,101-$9,600
|
0.80
|
%
|
$
|
9,601-$11,000
|
1.20
|
%
|
|||
Above 11,001
|
1.50
|
%
|
By:
|
/s/ LuAnn Via | ||||
Name:
|
LuAnn Via | /s/ Dolev Rafaeli | |||
Title:
|
Chairperson |
Dolev Rafaeli
|
Date:
|
Monday, April 2, 2018
|
Time:
|
8:30 am Eastern Time
|
Toll Free:
|
888-394-8218
|
International:
|
323-794-2149
|
Passcode:
|
6380302
|
Webcast:
|
www.strataskinsciences.com
|
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